dexamethasone / Generic mfg. - LARVOL DELTA

Long-Term Outcomes With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) Versus VRd in Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE-NDMM) in the Phase 3 PERSEUS Study (IMS 2026) - "A fter 6.8 y m FU , PERSEUS showed that pts treated with DVRd induction/ consolidation and DR maintenance achieved among the deepest and most durable responses seen in phase 3 NDMM studies . I mproved overall and sustained MRD neg rates seen since the primary analysis translate d into improved PFS and PFS2 , with an emerging OS benefit , even after per-protocol MRD-guided discontinuation of Dara maintenance . These findings reinforce DVRd -DR as the standard of care in TE-NDMM."

IO biomarker • Late-breaking abstract • P3 data • Hematological Malignancies • Multiple Myeloma • Transplantation

CERVINO: A Randomized Phase 3 Study of Etentamig vs Investigator's Choice of Standard Available Therapies in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Triple-Class Exposure (IMS 2026) - P3 | "Pts were randomized 1:1 to Etenta Q4W or SAT (carfilzomib + dexamethasone [Kd], elotuzumab + pomalidomide + d [EloPd], or selinexor + bortezomib + d [SVd]). In heavily pretreated pts with triple-class exposed RRMM, Etenta significantly improved ORR and PFS vs SAT, with an early positive OS signal. A single SUD andQ4Wdosing from initiation were associated with very low rates of CRS, ICANS, and ≥ G3 infections, reinforcing Etenta’s best-in-class safety potential. Data support Etenta monotherapy as a new standard of care with convenient dosing suitable for global outpatient and community use."

Clinical • Late-breaking abstract • P3 data • Hematological Malignancies • Infectious Disease • Inflammation • Multiple Myeloma

First-Year Results of Isatuximab-Iberdomide Maintenance in MRD-Positive Newly Diagnosed Multiple Myeloma Patients Included in the Phase 3 MIDAS Trial (IMS 2026) - P3 | "While daratumumab plus lenalidomide maintenance has shown efficacy in recent studies (PERSEUS, AURIGA), no data are available regarding anti-CD38 combined with a CELMoD in maintenance... MIDAS (NCT04934475) is an ongoing phase 3 trial evaluating an MRD-adapted consolidation and maintenance strategy in TE-NDMM patients treated with six cycles of isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd)... Maintenance with isatuximab plus iberdomide after Isa-KRd induction and single or tandem ASCT is feasible with a manageable safety profile. This combination induced substantial MRD conversion during the first year of maintenance in patients remaining MRD-positive after consolidation. These findings support further evaluation of anti-CD38 plus CELMoD-based maintenance strategies in high-risk NDMM patients."

Clinical • IO biomarker • Minimal residual disease • P3 data • Hematological Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Neutropenia

Discontinuation of Maintenance Therapy Guided by Minimal Residual Disease in Newly Diagnosed Multiple Myeloma: Long-Term Results of the GEM2014MAIN Study (IMS 2026) - " The GEM2014MAIN clinical trial randomly assigned lenalidomide and dexamethasone (RD) vs. ixazomib plus RD (IRD) as maintenance therapy in patients who received 6-cycles of induction therapy with bortezomib, lenalidomide and dexamethasone (VRD), followed by high-doses of melphalan or busulfan/melphalan and 2 consolidation cycles with VRD (GEM2012MENOS65 trial). Patients with MRDneg after two years of maintenance discontinued therapy and showed a significantly longer PFS than those with positive MRD that remained on maintenance. About half of the patients who were MRDneg at 2 years and discontinued maintenance remained alive and progression-free after 7 years and could be considered operationally cured."

Clinical • Minimal residual disease • Residual disease • Hematological Malignancies • Multiple Myeloma

5-Year Sustained Minimal Residual Disease (MRD) Negativity and Survival With Daratumumab Maintenance (D-Maint) in Transplant-Eligible (TE) NDMM: CASSIOPEIA Registry (IMS 2026) - "Introduction: CASSIOPEIA showed daratumumab, bortezomib, thalidomide, dexamethasone ( DVTd ) induction/autologous stem cell transplantation/consolidation improved outcomes vs VTd in TE - NDMM. After >8.5 y m FU with 96% retention, CASSIOPEIA registry data confirm deep and durable benefit of daratumumab tx . DVTd reduced risk of progression vs VTd by 38% and mortality by 39%. D - m aint demonstrated prolonged m PFS and PFS2 vs OBS ."

Clinical • Minimal residual disease • Residual disease • Transplantation

Iberdomide, Daratumumab, Dexamethasone (IberDd) vs Daratumumab, Bortezomib, Dexamethasone (DVd) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Results From EXCALIBER-RRMM Phase 3 Study (IMS 2026) - P3 | "This benefit was c onsistent across prespecified subgroups, including pts refractory to lenalidomide (LEN) in last LOT, pts with renal impairment, and ≥75y of age. IberDd led to a statistically significant and clinically meaningful improvement in MRD-negative CR vs DVd, with a manageable safety profile. IberDd represents an effective tx option for pts with RRMM as early as first relapse, that can be easily administered across diverse care settings."

Clinical • Late-breaking abstract • P3 data • Hematological Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Neutropenia • Renal Disease

The Benefit of Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone (DVRd) on Depth and Durability of Response in the Phase 3 CEPHEUS Trial: Updated Minimal Residual Disease Analysis (IMS 2026) - "In this analysis of CEPHEUS, DVRd led to clinically meaningful, deep responses, with higher overall MRDneg rates, and reported for the first time, 60-mo sustained MRDneg rates vs VRd across all time points in the ITT, MRD-evaluable, and TIE populations, translating to improved survival outcomes. These data further demonstrate that continued treatment with DVRd improves and deepens responses over time vs VRd in pts with NDMM."

Minimal residual disease • P3 data • Residual disease

MRD-Guided Frontline T-Cell Redirection Therapy for Newly Diagnosed High-Risk Multiple Myeloma Using Teclistamab-Daratumumab Intensification and Talquetamab-Daratumumab Early Rescue Intervention (IMS 2026) - P2 | "To evaluate the safety and preliminary efficacy of teclistamab-daratumumab (Tec-D) intensification following daratumumab-bortezomib-lenalidomide-dexamethasone (D-VRd) induction in ND-HRMM...CRS occurred in 7 patients (25%), all grade 1; only one required tocilizumab... Early MRD-guided incorporation of Tec-D intensification induced deep responses and high MRD-CR in ND-HRMM, supporting the evaluation of a full-immune based bispecific antibody-based, transplant-free approach in difficult to treat high-risk disease."

Late-breaking abstract • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Pneumonia • Respiratory Diseases

Evaluation of a Vision-Related Anamnestic Tool (VRAT) to Guide Belantamab Mafodotin Dosing With Bortezomib and Dexamethasone for Multiple Myeloma: Interim Results From the UKMRA ProMMise D Trial (IMS 2026) - "The symptom based VRAT approach demonstrated a low rate of false negative results demonstrating its potential to detect significant ocular AEs. Belamaf at Q8W dosing resulted in a low rate of G3-4 ocular events, leading to few dose delays and reductions. Funding: GSK: funding and Belamaf supply."

Hematological Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Neutropenia • Ophthalmology • Thrombocytopenia

Cevostamab Plus Pomalidomide (Pom) and Dexamethasone (Dex) Induces Durable Remissions in BCMA-Naïve Patients With Relapsed/Refractory Multiple Myeloma (RRMM): CAMMA 1 Arm B Extended Follow-up Data (IMS 2026) - P1 | "Cevostamab plus pom-dex induces durable remissions in BCMA-naïve pts with RRMM. Updated data will be presented."

Clinical • IO biomarker • Cerebral Hemorrhage • Hematological Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Neutropenia • Septic Shock • Thrombocytopenia • GPRC5D

Projecting Functional Cure in Patients (Pts) With Relapsed/Refractory Multiple Myeloma (RRMM) in the MajesTEC-3 Study of Teclistamab-Daratumumab (Tec-Dara) Using a Mixture Cure Model (IMS 2026) - P3 | "Introduction: In the phase 3 MajesTEC-3 study (NCT05083169) , Tec-Dara significantly improved progression-free survival (PFS; HR 0.17; 95% CI 0.12–0.23) and overall survival (OS; HR 0.46; 95% CI 0.32–0.65) vs Dara plus dexamethasone with pomalidomide or bortezomib (DPd/DVd) in pts with RRMM and 1–3 prior lines of therapy ( median follow-up 34.5 mo) . Best fit models estimated >85% cure fractions for OS and PFS in Tec-Dara pts in MajesTEC-3. While functional cure does not imply biological/clinical cure, the analysis suggests that a substantial fraction of Tec-Dara-treated pts will experience a mortality risk and projected life expectancy similar to the general population. MajesTEC-3 is ongoing, and if continued follow-up confirms the model-based predictions, Tec-Dara may help redefine survival expectations in RRMM"

Clinical • Hematological Malignancies • Multiple Myeloma

Overall Survival, Progression and Non-Relapse Mortality With Teclistamab Plus Daratumumab (Tec-Dara) vs Dara-Based Triplets in Relapsed/Refractory Multiple Myeloma (RRMM): MajesTEC-3 Post Hoc Analysis (IMS 2026) - "Introduction: Tec-Dara showed significant survival benefits vs Dara + dexamethasone + pomalidomide/bortezomib (DPd/DVd) in MajesTEC-3 in early-line RRMM, a setting in which disease progression is the leading cause of death... Patients (pts) had 1–3 prior lines of therapy (LOT), including a proteasome inhibitor and lenalidomide (len; len-refractory if 1 prior LOT) with progression on/after last LOT... Tec-Dara significantly improved OS over DPd/DVd in pts with RRMM and 1–3 prior LOT. This analysis demonstrates that the observed OS benefit is driven by a profound reduction in disease progression, the leading cause of mortality in RRMM. Despite early curve crossing, Tec-Dara did not increase NRM."

Clinical • Retrospective data • Hematological Malignancies • Multiple Myeloma

48-Month Survival Analysis of the BENEFIT Trial, Isatuximab Plus Bortezomib, Lenalidomide, and Dexamethasone for Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients (IMS 2026) - P3 | "The PFS remains not statistically different when restricting analysis to the first 48 months in BENEFIT, but long term PFS modeling suggests that difference is to be expected. These results support the clinically meaningful benefit of the Isa-VRd regimen compared to IsaRd in TI NDMM patients, including HRMM. This data supports Isa-VRd as a new SOC for TI NDMM patients aged of 65 to 79 years."

Clinical • Late-breaking abstract • Hematological Malignancies • Multiple Myeloma • Transplantation

Phase 2 Study of Talquetamab (Tal), Daratumumab (D), and Lenalidomide (R) as Induction Therapy in Patients (Pts) With Transplant Eligible Newly Diagnosed Multiple Myeloma (TE-NDMM): MajesTEC-5 (IMS 2026) - " Eligible pts aged 18–70 years with TE-NDMM received Tal-DR induction therapy: Tal 0.8 mg/kg SC Q4W, preceded by 3 step-up doses in cycle (C)1; D 1800 mg SC QW in C1–2 and Q2W in C3–6; oral R 25 mg in C2–6; and dexamethasone 20 mg in C1–2 only. Tal-DR induction demonstrated promising early efficacy results in TE-NDMM, with rapid, deep responses and high MRD-negative rates. The gr 3-4 infection rate was lower than previously reported for the teclistamab induction therapy arms of this study, and no new safety signals emerged. This suggests pts at high risk for infection may benefit from targeting non-BCMA myeloma antigens."

Clinical • P2 data • Ataxia • Atopic Dermatitis • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Mood Disorders • Movement Disorders • Multiple Myeloma • Neutropenia • Otorhinolaryngology • Transplantation • Vertigo • CD34

Teclistamab Plus Talquetamab Consolidation in Newly Diagnosed Myeloma Patients With Positive Measurable Residual Disease After DVRD Induction : Interim Analysis of the Phase 2 Study IFM 2022-01 (IMS 2026) - P2 | "IFM 2022-01 is a phase 2 trial evaluating tec plus tal or tec plus lenalidomide consolidation in TE-NDMM patients according to measurable residual disease (MRD) after Daratumumab Bortezomib Lenalidomide Dexamethasone (D-VRd) induction. The combination of tec+tal resulted in early and high undetectable MRD rates in NDMM patients with detectable MRD after D-VRD induction. These preliminary data showed no new safety signal was observed with tec+tal used in frontline."

Clinical • P2 data • Residual disease • Hematological Malignancies • Infectious Disease • Multiple Myeloma

DREAMM-9 Patient-Reported Vision-Related Function With Extended Belantamab Mafodotin Dosing Intervals With Bortezomib, Lenalidomide, Dexamethasone (BVRd) in Transplant Ineligible Multiple Myeloma (IMS 2026) - P1 | "BVRd has high efficacy and is well tolerated highlighting the promise of this regimen . Ocular events were transient and pts in the Q9/12W or Q12W group had less severe blurred vision than the Q3/4W group. Extended dosing schedules were generally not associated with meaningful deterioration of VRF."

Clinical • Hematological Malignancies • Multiple Myeloma • Transplantation

Comparative Analysis of Isa SC Vrd (ISASOCUT, Weekly Bortezomib) and Isa IV Vrd (IMROZ, Twice-Weekly Bortezomib): 20-Month Follow-Up in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients (IMS 2026) - P=N/A, P3 | "Introduction: Intravenous (IV) isatuximab (Isa) plus bortezomib (V), lenalidomide (R), and dexamethasone (d) is approved for patients (pts) with transplant-ineligible newly diagnosed multiple myeloma (Ti NDMM) based on the phase 3 IMROZ trial (NCT03319667). This comparative analysis at 20 mos of follow-up found comparable efficacy with greater tolerability for Isa SC OBI (QW V) than Isa IV (BIW V) for PN and IRRs. This analysis demonstrated Isa SC OBI as an efficacious and well-tolerated treatment for Ti NDMM pts."

Clinical • Hematological Malignancies • Multiple Myeloma • Plasmacytoma • Transplantation

(DARA)/BORTEZOMIB/LENALIDOMIDE/DEXAMETHASONE (D-VRD) WITH D-R MAINTENANCE (MAINT) IN TRANSPLANT-ELIGIBLE (TE) NEWLY DIAGNOSED MYELOMA (NDMM): ANALYSIS OF PERSEUS BASED ON CYTOGENETIC RISK (EBMT 2025) - P3 | "Background: In the primary analysis of the phase 3 PERSEUS study, subcutaneous DARA (DARA SC) + VRd induction/consolidation (ind/consol) and D-R maint improved progression-free survival (PFS) and increased rates of deep and durable responses vs VRd ind/consol and R maint in TE NDMM, regardless of cytogenetic risk. The addition of DARA SC to VRd ind/consol and to R maint provided clinical benefit in terms of PFS and induced higher rates of deep and sustained responses vs VRd ind/consol and R maint across all cytogenetic risk subgroups. This supports D-VRd ind/consol and D-R maint as a new standard of care for TE NDMM, regardless of cytogenetic risk. Clinical Trial Registry: https://www.clinicaltrials.gov/study/NCT03710603"

Clinical • Hematological Malignancies • Multiple Myeloma • Oncology • Transplantation

Etentamig Combined With Pomalidomide Plus Dexamethasone (Pom+Dex) in Relapsed/Refractory Multiple Myeloma (RRMM) After 1-3 Prior Lines of Therapy: A Phase 1b Dose-Escalation and Safety Expansion Study (IMS 2026) - P1 | " Arm E of this multi-arm, open-label, multicenter, Phase 1b dose-escalation and -expansion study enrolled pts ≥18 years old with RRMM after 1–3 PLT, including lenalidomide. Consistent with the previously reported Arm A data, the etentamig plus pom+dex combination led to deep responses. Considering the shorter Arm E follow-up time, the introduction of a single SUD, as well as delayed pom administration in Arm E, further reduced CRS and infection risk, mirroring etentamig monotherapy rates. These data support further exploration of the regimen in a randomized Phase 3 study."

Clinical • P1 data • Hematological Disorders • Hematological Malignancies • Infectious Disease • Inflammation • Multiple Myeloma • Neutropenia

Dara-VRD Plus Tandem Autologous Stem Cell Transplantation Followed by Prolonged Consolidation for Primary Plasma Cell Leukemia: A French Phase II Prospective Trial (IMS 2026) - "The treatment strategy consisted of four cycles of DVRD (daratumumab, bortezomib, lenalidomide, dexamethasone) as induction, followed by a first autologous stem cell transplantation (ASCT). These initial results suggest that DVRD combined with tandem ASCT is feasible and induces high hematological response rates in patients with PCL, a population with a particularly poor prognosis. This strategy may translate into improved survival outcomes. Future trials will explore combinations of DVRD and ASCT with anti-BCMA bispecific antibodies."

Clinical • IO biomarker • P2 data • Hematological Malignancies • Infectious Disease • Leukemia • Plasma Cell Leukemia • Transplantation

Assembled Hyaluronic Acid Therapeutics for Targeting M1 Macrophages and Regulating Immune Homeostasis for Ulcerative Colitis Treatment. (PubMed, Adv Sci (Weinh)) - "Single-cell RNA-sequencing corroborates these shifts and maps the myeloid, B and T-cell programs, highlighting the downregulated inflammatory responses following uhNAs treatment. Notably, uhNAs-OA outperform physical HA (or HA-PBA)/oleic-acid mixtures, and two clinically established IBD drugs (5-aminosalicylic acid and dexamethasone), protecting mice models against both acute and chronic colitis."

Journal • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis • CD8

Prophylaxis with dexamethasone or anakinra in patients with high-risk large B cell lymphoma treated with axicabtagene ciloleucel. (PubMed, Transplant Cell Ther) - No abstract available

Journal • B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

The Rare Case of a Sertoli Cell Tumor of the Adrenal Gland in a Man With Pathological Dexamethasone Suppression Test: A Case Report. (PubMed, Cureus) - "Postoperatively, hydrocortisone replacement was initiated due to a submaximal cortisol response to adrenocorticotropic hormone (ACTH) stimulation testing. In this case, robotic-assisted adrenalectomy proved safe and feasible. We observed good short-term oncological and clinical outcomes. Further reports are needed to clarify hormonal associations and establish standardized follow-up and treatment strategies."

Journal • Adrenal Cortex Carcinoma • Endocrine Disorders • Nephrology • Oncology • Solid Tumor • AFP • CD99 • DICER1 • FOXL2 • MLANA • NCAM1 • SYP

Intrathecal dexamethasone in FIRES. (PubMed, Epilepsy Res) - "IT-DEX may represent a promising therapeutic option for FIRES, particularly in children and adolescents. Our findings provide preliminary evidence supporting its potential use, with administration at 72-hour intervals to a cumulative dose of 1 mg/kg emerging as a potentially reasonable approach. However, further studies are required to determine its optimal dosing, safety and efficacy."

Journal • Review • Anesthesia • CNS Disorders • Epilepsy • Infectious Disease

POSTOPERATIVE NAUSEA AND VOMITING AFTER ENDOSCOPIC SLEEVE GASTROPLASTY UNDER TIVA AND MULTIMODAL MODIFIED ANTIEMETIC PROPHYLAXIS (UEGW 2026) - "All patients received TIVA (propofol 2 mg/kg induction, 10 mg/kg/h infusion; remifentanil 0.05 µg/kg/min) and a standardized antiemetic regimen (fosaprepitant 150 mg, granisetron 3 mg, dexamethasone 8 mg at the beginning, and haloperidol 1 mg at the end of the procedure). In this case series, the combination of transoral, non-pneumoperitoneum ESG with TIVA and an aggressive multimodal antiemetic regimen was associated with the absence of clinically significant PONV. Previous studies support multimodal prophylaxis (4). Despite the high baseline risk, no clinically significant PONV was observed, suggesting a potential benefit of combining TIVA with an aggressive multimodal approach."